Conestoga Capital Advisors LLC Reduces Holdings in Alpha Teknova, Inc.

Conestoga Capital Advisors LLC has decreased its holdings in shares of Alpha Teknova, Inc. (NASDAQ:TKNO) by 19.9% during the fourth quarter, according to a recent filing with the Securities and Exchange Commission. As of the end of the fourth quarter, the institutional investor owned 244,344 shares of the company after selling 60,785 shares during the quarter. This represents approximately 0.46% of Alpha Teknova’s total stock, valued at around $2,040,000.

Alpha Teknova serves the biotechnology sector by producing essential reagents for research and development. The company creates pre-poured media plates, as well as cell culture media and molecular biology reagents that are vital for cell growth and manipulation.

Changes in Institutional Holdings

Other institutional investors have also made adjustments to their positions in Alpha Teknova. China Universal Asset Management Co. Ltd. entered a new stake in Alpha Teknova worth about $94,000 during the fourth quarter. Similarly, Whalen Wealth Management Inc. acquired a new stake valued at approximately $240,000. State Street Corp increased its position by 249.3% in the third quarter, acquiring an additional 54,700 shares, bringing their total to 76,645 shares worth $371,000. Geode Capital Management LLC also raised its holdings by 24.4% in the same quarter, now owning 188,173 shares valued at $911,000. Point72 Asset Management L.P. is another institutional investor that purchased a new stake worth approximately $1,483,000 during the third quarter. Currently, around 13.81% of Alpha Teknova's shares are owned by institutional investors.

Stock Performance Overview

As of Monday, Alpha Teknova’s shares opened at $8.59. The company has a market capitalization of $457.67 million, a P/E ratio of -11.61, and a beta of 0.34. Over the past year, Alpha Teknova’s shares have fluctuated between a low of $1.15 and a high of $10.37. The stock’s moving averages show a 50-day average of $8.23 and a 200-day average of $6.21. Financial ratios indicate a debt-to-equity ratio of 0.12, a current ratio of 4.73, and a quick ratio of 3.94.

Earnings Report and Analyst Predictions

Alpha Teknova recently announced its earnings report on November 7. The company reported a loss of ($0.15) per share for the quarter, which missed the consensus estimate of ($0.11) by $0.04. The company exhibited a negative return on equity of 35.30% and a net margin of -87.17%. However, the revenue for the quarter was reported at $9.58 million, exceeding the anticipated $9.30 million. A year prior, the company reported a loss of ($0.34) per share. Analysts predict that Alpha Teknova, Inc. could post an EPS of -0.58 for the current fiscal year.

About Alpha Teknova

Alpha Teknova, Inc. plays a crucial role in the biotechnology sector by designing and manufacturing key reagents for the development of therapies, vaccines, and diagnostics. The products they offer are integral to ongoing biomedical research and commercial applications both in the United States and globally.

Investment Consideration

If you're considering whether to invest $1,000 in Alpha Teknova, it's essential to think critically. While this company currently holds a "Moderate Buy" rating, some analysts suggest there are other stocks that may present better investment opportunities.

Investment, Finance, Stock